Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities

2011429 citationsReviewhybrid Open Access

Authors

Mario E. Lacouture · Memorial Sloan Kettering Cancer Center

Milan J. Anadkat · Washington University in St. Louis

René‐Jean Bensadoun · Centre Hospitalier Universitaire de Poitiers

Jane Bryce · Tumori Foundation

Alexandre Chan · National University of Singapore

Joel B. Epstein · University of Illinois Chicago

Beth Eaby‐Sandy

Abstract

Prevention and management of EGFRI-related dermatologic toxicities is critical to maintain patients' health-related quality of life and dose intensity of antineoplastic regimens. More rigorous investigation of these toxicities is warranted to improve preventive and treatment strategies.

Topics & Keywords

Cancer Diagnosis and Treatment Colorectal Cancer Treatments and Studies Chemotherapy-related skin toxicity

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Supportive Care in Cancer

Volume 19, Issue 8, pp. 1079-1095

DOI: 10.1007/s00520-011-1197-6

Field-Weighted Citation Impact: 12.41